Biomarkers in the Central Nervous System
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Biomarkers in CNS are expected to be an area that will witness strong growth in the future due to factors such as deeper understanding of the underlying disease pathology, advancements in technologies, and potential of these biomarkers that can contribute to targeted therapy. Biomarkers in CNS targeting a number of neurology indications are being developed; however, the most common ones are Alzheimer’s disease (AD), Schizophrenia and Multiple Sclerosis (MS).
This report provides an overview of current clinical and product development trends for Biomarkers in CNS within the 8MM (France, Germany, Italy, Spain, UK, US, Japan, China), including analysis of the most common targets and molecule types that are being evaluated among the current biomarkers, focus on product development in indications such as AD, Schizophrenia MS, and unmet needs within biomarkers in CNS.
Scope
GlobalData’s Biomarkers in the Central Nervous System report combines primary research from a cross-specialty panel of neurology experts with in-house analyst expertise to provide an assessment of the development landscape.
Components of the slide deck include primary and secondary research:
• Quotes from 6 key opinion leaders (3 US, 1 EU, 2 Japan) and 2 payers (1 US and 1 UK)
• Summary of biomarkers product definitions and classifications
• Overview of common targets and molecule types among current biomarkers, with focus on product development in AD, Schizophrenia and MS
• Trends in ongoing clinical trials in biomarkers in CNS based on sponsor type, and phase of development
• Call-outs of key information and details
• Insight from GlobalData’s specialist neurology analysts
Reasons to Buy
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the global Glaucoma market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Glaucoma market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
InviCRO
Lunbeck
Eisai
F. Hoffmann- La Roche
J&J
Biogen
GSK
Eli Lilly
Brystol-Myers Squibb
Regenera Pharma
Araclon Biotech
EIP Pharma
Sunnybrook Health Sciences Centre
AstraZeneca
Boehringer Ingelheim
Les Laboratoires Servier
GE Healthcare
Piramal
Forest Laboratories
Alkermes
Sunovion Pharmaceuticals
Intra-Cellular Therapies
GW Pharmaceuticals
Novartis
Merck
Teva
Genzyme
AbbVie
Pfizer
Table of Contents
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.